Fig. 2: Kaplan–Meier estimates of overall survival probability (final analysis) for first-line trifluridine/tipiracil plus bevacizumab (TT-B; n = 77) and capecitabine plus bevacizumab (C-B; n = 76) in patients with metastatic colorectal cancer who were ineligible for intensive chemotherapy. | British Journal of Cancer

Fig. 2: Kaplan–Meier estimates of overall survival probability (final analysis) for first-line trifluridine/tipiracil plus bevacizumab (TT-B; n = 77) and capecitabine plus bevacizumab (C-B; n = 76) in patients with metastatic colorectal cancer who were ineligible for intensive chemotherapy.

From: First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Fig. 2

CI confidence interval, HR hazard ratio.

Back to article page